Nucleix Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Private

  • Employees
  • 70

Employees

  • Latest Deal Type
  • Series E

  • Latest Deal Amount
  • $77M

  • Investors
  • 13

Nucleix General Information

Description

Developer of liquid biopsy technology designed for early-stage and recurring cancer detection. The company's technology utilizes PCR-based epigenetics and machine learning algorithms to identify DNA methylation patterns in urine and blood samples, enabling healthcare operators and patients with non-invasive diagnostic tests that deliver objective numerical results for bladder and lung cancer monitoring.

Contact Information

Website
www.nucleix.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3 Pekeris Street
  • Rehovot 7670203
  • Israel
+972
Primary Industry
Diagnostic Equipment
Other Industries
Other Healthcare Technology Systems
Corporate Office
  • 3 Pekeris Street
  • Rehovot 7670203
  • Israel
+972

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nucleix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series E) 01-Dec-2021 $77M Completed Product Development
6. Later Stage VC 01-Mar-2021 Completed Product Development
5. Grant 30-Jul-2018 Completed Pre-Clinical Trials
4. Later Stage VC (Series B) 23-May-2016 Completed Pre-Clinical Trials
3. Grant 22-Mar-2016 Completed Pre-Clinical Trials
2. Later Stage VC (Series A) 12-May-2014 $5.4M $8.4M Completed Pre-Clinical Trials
1. Angel (individual) $3M $3M Completed Startup
To view Nucleix’s complete valuation and funding history, request access »

Nucleix Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series AA3
Series AA2
Series AA1
Ordinary C
Ordinary B 950,000 $1.12 $1.12 1x $1.12 3.04%
Ordinary A 900,000 $1.12 $1.12 1x $1.12 2.88%
To view Nucleix’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Nucleix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of liquid biopsy technology designed for early-stage and recurring cancer detection. The company's technology
Diagnostic Equipment
Rehovot, Israel
70 As of 2026

Hayward, CA
 

Vista, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nucleix Competitors (37)

One of Nucleix’s 37 competitors is Predicine, a Venture Capital-Backed company based in Hayward, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Predicine Venture Capital-Backed Hayward, CA
Mindera Health Venture Capital-Backed Vista, CA
Fluxion (Diagnostic Equipment) Formerly VC-backed Alameda, CA
Vortex Biosciences Venture Capital-Backed Manchester, United Kingdom
OncoDNA Venture Capital-Backed Gosselies, Belgium
You’re viewing 5 of 37 competitors. Get the full list »

Nucleix Patents

Nucleix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025141580-A1 Methods for preparing dna sequencing libraries Inactive 31-Dec-2023
WO-2025097008-A2 Mitochondrial dna intrinsic controls for use in msre-dependent dna methylation analysis Inactive 01-Nov-2023
WO-2025097008-A3 Mitochondrial dna intrinsic controls for use in msre-dependent dna methylation analysis Inactive 01-Nov-2023
AU-2024331615-A1 Fragmentomics-based plasma separation assays Pending 28-Aug-2023
EP-4771179-A1 Fragmentomics-based plasma separation assays Pending 28-Aug-2023 C12Q1/686
To view Nucleix’s complete patent history, request access »

Nucleix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nucleix Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
BlackRock Asset Manager Minority
Gefen Capital Venture Capital Minority
Mirae Asset Capital Venture Capital Minority
Sands Capital Growth/Expansion Minority
LAV (Lilly Asia Fund) Corporate Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

Nucleix FAQs

  • When was Nucleix founded?

    Nucleix was founded in 2008.

  • Where is Nucleix headquartered?

    Nucleix is headquartered in Rehovot, Israel.

  • What is the size of Nucleix?

    Nucleix has 70 total employees.

  • What industry is Nucleix in?

    Nucleix’s primary industry is Diagnostic Equipment.

  • Is Nucleix a private or public company?

    Nucleix is a Private company.

  • What is the current valuation of Nucleix?

    The current valuation of Nucleix is .

  • What is Nucleix’s current revenue?

    The current revenue for Nucleix is .

  • How much funding has Nucleix raised over time?

    Nucleix has raised $143M.

  • Who are Nucleix’s investors?

    BlackRock, Gefen Capital, Mirae Asset Capital, Sands Capital, and LAV (Lilly Asia Fund) are 5 of 13 investors who have invested in Nucleix.

  • Who are Nucleix’s competitors?

    Predicine, Mindera Health, Fluxion (Diagnostic Equipment), Vortex Biosciences, and OncoDNA are some of the 37 competitors of Nucleix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process